Table 2 Clinical properties of patients... | American Society of Hematology

Table 2

Clinical properties of patients who had tumor ROS levels measured

Patient no.	Sex	Age, y	Disease duration, y	Rai stage	CD3, %	WBC, × 10⁶/mL	Cytogenetics	LDT, mo	No. of treatments†	ROS‡
201	M	30	2	0	1	26	Normal	24	0	730
202	M	72	1	4	1	51	13q−	30	0	833
203	F	73	1	0	1	27	NA	NA	0	972
204	M	57	3	0	35	32	NA	16	0	699
205	F	68	2	3	67	50	NA	11	0	742
206	F	61	4	3	10	82	11q	3	0	1078
207	F	64	2	0	0	27	13q	30	0	691
208	M	62	7	0	4	22	NA	60	0	414
209	M	83	8	4	1	111	Normal	12	1	653
210	F	62	27	4	18	752	11q−,13q−	15	2	1780
211	M	61	11	4		191	17p−	2	4	2008
212	M	74	4	4	95	82	NA	12	0	931
213	F	35	5	4	8	135	13q−	12	0	841
214	M	71	13	4	5	138	13q−	7	4	1204
215	M	57	8	1		40	NA	40	0	639
216	M	67	2	4	1	65	13q−	13	0	962
217	M	55	6	4	81	40	13q−,17p−	6	4	1896
218	M	64	6	4	20	152	13q−,17p−, 11q−	4	4	2066
219	M	55	1	4	1	58	13q−	8	0	1529
220	F	58	2	4	1	74	NA	18	0	667
221	M	57	7	4	21	27	11q−	3	4	1379
222	M	59	8	2	25	43	Normal	40	0	696
223	M	64	7	2	15	43	Normal	17	1	740
224	M	60	15	4	49	66	11q−	5	6	1712
225	F	79	2	0	73	13	T12	45	0	830
226	M	70	8	4	4	20	Normal	7	1	1256
227	M	54	6	3	3	37	13q−	36	1	1016
228	F	79	6	0	16	47	13q−	48	0	695
229	M	75	6	4	31	248	NA	11	1	1852
230	M	53	1	0	1	13	NA	NA	0	299
231	M	57	1	0	2	27	13q−	30	0	734
232	M	67	6	0	1	24	NA	55	0	422
233	F	62	7	3	20	109	T12	9	1	734
301	F	69	8	3	77	97	Normal	16	0	NA
302	M	49	9	4	12	151	NA	4	0	NA
303	M	61	3	4	2	70	NA	4	1	NA
304	F	83	13	3	8	206	T12	10	1	NA
305	F	71	6	4	5	142	NA	8	2	NA
306	F	87	2	4	6	31	NA	24	0	NA
307	M	59	6	4	1	115	13q−	30	1	NA

Patient no.	Sex	Age, y	Disease duration, y	Rai stage	CD3, %	WBC, × 10⁶/mL	Cytogenetics	LDT, mo	No. of treatments†	ROS‡
201	M	30	2	0	1	26	Normal	24	0	730
202	M	72	1	4	1	51	13q−	30	0	833
203	F	73	1	0	1	27	NA	NA	0	972
204	M	57	3	0	35	32	NA	16	0	699
205	F	68	2	3	67	50	NA	11	0	742
206	F	61	4	3	10	82	11q	3	0	1078
207	F	64	2	0	0	27	13q	30	0	691
208	M	62	7	0	4	22	NA	60	0	414
209	M	83	8	4	1	111	Normal	12	1	653
210	F	62	27	4	18	752	11q−,13q−	15	2	1780
211	M	61	11	4		191	17p−	2	4	2008
212	M	74	4	4	95	82	NA	12	0	931
213	F	35	5	4	8	135	13q−	12	0	841
214	M	71	13	4	5	138	13q−	7	4	1204
215	M	57	8	1		40	NA	40	0	639
216	M	67	2	4	1	65	13q−	13	0	962
217	M	55	6	4	81	40	13q−,17p−	6	4	1896
218	M	64	6	4	20	152	13q−,17p−, 11q−	4	4	2066
219	M	55	1	4	1	58	13q−	8	0	1529
220	F	58	2	4	1	74	NA	18	0	667
221	M	57	7	4	21	27	11q−	3	4	1379
222	M	59	8	2	25	43	Normal	40	0	696
223	M	64	7	2	15	43	Normal	17	1	740
224	M	60	15	4	49	66	11q−	5	6	1712
225	F	79	2	0	73	13	T12	45	0	830
226	M	70	8	4	4	20	Normal	7	1	1256
227	M	54	6	3	3	37	13q−	36	1	1016
228	F	79	6	0	16	47	13q−	48	0	695
229	M	75	6	4	31	248	NA	11	1	1852
230	M	53	1	0	1	13	NA	NA	0	299
231	M	57	1	0	2	27	13q−	30	0	734
232	M	67	6	0	1	24	NA	55	0	422
233	F	62	7	3	20	109	T12	9	1	734
301	F	69	8	3	77	97	Normal	16	0	NA
302	M	49	9	4	12	151	NA	4	0	NA
303	M	61	3	4	2	70	NA	4	1	NA
304	F	83	13	3	8	206	T12	10	1	NA
305	F	71	6	4	5	142	NA	8	2	NA
306	F	87	2	4	6	31	NA	24	0	NA
307	M	59	6	4	1	115	13q−	30	1	NA

NA indicates not available; and WBC, white blood cell.

*Normal range is 0.6 to 2.3 mg/mL.

†

Splenectomy, conventional chemotherapeutic regimens, such as fludarabine/cyclophosphamide (FC), and steroid-based regimens are each considered as a treatment.

‡

Mean fluorescence intensity of DCFH staining.

View Large

This Feature Is Available To Subscribers Only